TRAVERE THERAPEUTICS, INC. Contract with Customer, Performance Obligation Satisfied in Previous Period
TRAVERE THERAPEUTICS, INC. (TVTX) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $1.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2026-03-31 was $1.00M, a 150.00% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-12-31 was $2.10M.
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-09-30 was -$2.30M, a 866.67% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2025 was $1.10M, a 120.00% increase from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $500.00K, a 25.00% increase from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $400.00K, a 100.00% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2022 was $200.00K, a 0.00% change from fiscal 2021.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month as first filed | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.00M 10-Q · filed 2026-08-04 | $3.10M derived: sum of 3 quarters · filed 2026-08-04 | $800.00K derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-04 | $3.10M derived: sum of 2 quarters · filed 2026-05-04 | $800.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.70M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$200.00K derived: sum of 2 quarters · filed 2026-02-19 | $700.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.10M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | -$2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$1.40M derived: sum of 2 quarters · filed 2026-08-04 | -$1.00M 10-Q · filed 2025-10-30 | -$1.00M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.30M 10-Q · filed 2026-08-04 | -$1.30M 10-Q · filed 2025-08-06 | $1.30M derived: sum of 3 quarters · filed 2026-08-04 | $1.60M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-04 | $400.00K derived: sum of 2 quarters · filed 2026-05-04 | $700.00K derived: sum of 3 quarters · filed 2026-05-04 | $800.00K derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $300.00K derived: sum of 2 quarters · filed 2026-02-19 | $400.00K derived: sum of 3 quarters · filed 2026-02-19 | $500.00K 10-K · filed 2026-02-19 | -$500.00K 10-K · filed 2025-02-21 | |
| 2024-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $400.00K derived: sum of 2 quarters · filed 2025-10-30 | $500.00K 10-Q · filed 2025-10-30 | $500.00K derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2024-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $200.00K 10-Q · filed 2025-08-06 | $200.00K derived: sum of 3 quarters · filed 2026-02-19 | |||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-01 | $100.00K derived: sum of 2 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $400.00K 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | $400.00K 10-Q · filed 2024-10-31 | |||||
| 2023-03-31 | $400.00K 10-Q · filed 2023-05-04 | |||||
| 2022-12-31 | $200.00K 10-K · filed 2025-02-21 | $800.00K 10-K · filed 2023-02-23 | ||||
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | $200.00K 10-K · filed 2024-02-20 | $400.00K 10-K · filed 2023-02-23 | ||||
| 2020-12-31 | $400.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |